Age-related Changes in Sleep-wake Regulation

Sleep Deprivation Clinical Trial

Official title:

Age-related Changes in Sleep-wake Regulation: Effects of Sleep Loss on Possible Molecular Markers of Sleep Need

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03813082
• Other study ID #: PSS-Sleep
• Status: Completed
• Phase: N/A
• Start date: March 1, 2016
• Est. completion date: December 2019

Study information

• Verified date: January 2021
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A sleep deprivation protocol combined with state-of-the-art, simultaneous positron emission tomography and magnetic resonance spectroscopy imaging will be employed to investigate the effects of sleep deprivation and aging on hypothesized molecular markers of sleep need.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: December 2019
• Est. primary completion date: September 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• healthy male individuals

• age: 20-35 or 60-70 years

• right-handed

• non-smokers

• moderate caffeine/alcohol consumption

• normal BMI

Exclusion Criteria:

• Sleep/circadian rhythms disturbances

• former brain injuries with loss of consciousness and brain anomalies

• drug intake/consumption

• medication intake

• cardiac pacemaker

• neurological disorders

• prior participation (during past 2 years) in radiological or nuclear experiment

Related Conditions & MeSH terms

• Sleep Deprivation

Intervention

Behavioral:
• Prolonged wakefulness
40 hours of prolonged wakefulness

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sleep-wake induced change in cerebral availability of mGluR5 (metabotropic glutamate receptors of subtype 5)	Positron emission tomography	Change from baseline metabotropic glutamate receptors of subtype 5 availability after 33 hours of prolonged wakefulness and 8 hours of recovery sleep
Secondary	Sleep-wake induced change in glutamate concentration in prefrontal cortex and basal ganglia	Magnetic resonance spectroscopy	Change from baseline glutamate concentration after 33 hours of prolonged wakefulness and 8 hours of recovery sleep
Secondary	Sleep-wake induced change in potential molecular markers of sleep need	microRNAs, fragile X mental retardation protein, and brain-derived neurotrophic factor concentrations in peripheral blood	Change from baseline microRNA, fragile X mental retardation protein and brain-derived neurotrophic factor concentrations after 33 hours of prolonged wakefulness and 8 hours of recovery sleep
Secondary	Sleep-wake induced change in sleep electroencephalogram (EEG)	Spectral composition of the EEG during sleep	Change from all-night baseline sleep EEG in 8 hours of recovery sleep after 33 hours of prolonged wakefulness
Secondary	Sleep-wake induced change in waking electroencephalogram (EEG)	Spectral composition of the EEG in wakefulness	Change from baseline waking EEG during 33 hours of prolonged wakefulness and after 8 hours of recovery sleep
Secondary	Sleep-wake induced change in subjective state	Subjective sleepiness as quantified with the Stanford Sleepiness Scale (range: 1 to 7)	Change from baseline sleepiness during 33 hours of prolonged wakefulness and after 8 hours of recovery sleep
Secondary	Sleep-wake induced change in cognitive performance	Cognitive performance battery including tasks measuring sustained attention, executive functioning and working memory	Change from baseline cognitive performance during 33 hours of prolonged wakefulness and after 8 hours of recovery sleep